Pure red cell aplasia

Article written and reviewed by Dr Luca Moretti

Pure red cell aplasia (PRCA, Pure Red Cell Aplasia) is a rare hematologic syndrome characterized by selective arrest of erythrocyte production in the bone marrow, with preservation of the granulocytic and megakaryocytic lineages. The clinical picture is dominated by severe, normocytic, normochromic, profoundly hyporegenerative anemia, often accompanied by progressive fatigue, dyspnea even at rest, and cutaneous and mucosal pallor. The reticulocyte count is markedly reduced, while leukocytes and platelets are generally within normal limits unless associated conditions are present. From a pathophysiologic perspective, PRCA is a paradigm of selective erythropoietic failure that may present as a primary idiopathic entity or as a syndrome secondary to multiple underlying conditions, some of which are reversible with targeted treatment. Early diagnosis and precise identification of the cause are fundamental because management differs radically according to etiology and associated comorbidities.

Etiology and risk factors

Pure red cell aplasia may result from a wide range of direct causes, whose identification is essential both for prognostic assessment and therapeutic selection. In a substantial proportion of adult patients, PRCA is idiopathic, without an evident trigger; in these cases, the most recent scientific research suggests an immune mediated origin, with selective destruction of erythroid precursors by autoreactive T lymphocytes or specific autoantibodies.

Among well documented etiologies, the most common cause of acute and subacute forms is viral infection, particularly parvovirus B19. This pathogen, which has a selective tropism for erythroid precursors, uses transferrin receptor 1 (TfR1/CD71) through VP1u for cell entry; globoside (P antigen) acts at a postentry stage. Persistent parvovirus B19 associated PRCA is typical of immunocompromised individuals, such as transplant recipients, patients with immunodeficiency, those receiving immunosuppressive therapy, or those with HIV infection, in whom viral persistence prevents erythropoietic recovery. In patients with chronic hemolytic anemias, B19 infection instead typically causes a transient aplastic crisis.

A second well established etiologic category is paraneoplastic PRCA, most often associated with thymoma but also observed with lymphoproliferative disorders such as chronic lymphocytic leukemia and lymphomas. In these cases, pathogenesis involves autoimmunity or dysregulation of immune surveillance, resulting in selective attack on the erythroid lineage.

Systemic autoimmune diseases are also documented causes of pure red cell aplasia: systemic lupus erythematosus, rheumatoid arthritis, and other connective tissue diseases can induce an erythroblast maturation block through autoantibodies or profound alterations in the bone marrow microenvironment.

No less relevant in clinical practice is drug induced PRCA or PRCA caused by chemical agents: chloramphenicol, some antiepileptic drugs, isoniazid, azathioprine, allopurinol, and a range of other agents are recognized as potential causes of direct or immune mediated erythroblast inhibition. In selected cases, prompt withdrawal of the triggering agent is followed by gradual erythropoietic recovery.

A rare iatrogenic form is PRCA caused by neutralizing anti-erythropoietin antibodies, described in patients exposed to erythropoiesis stimulating agents. It should be suspected when abrupt severe anemia with marked reticulocytopenia develops during ESA therapy and requires specialist immunologic confirmation and withdrawal of the causative agent.

Cases of PRCA after allogeneic hematopoietic stem cell transplantation have also been described, particularly in the presence of major or bidirectional ABO incompatibility, in which persistence of anti-donor isohemagglutinins produced by residual recipient plasma cells or lymphocytes may selectively suppress donor erythropoiesis.

Alongside acquired forms, congenital PRCA must be distinguished because of its different etiopathogenesis and natural history: the paradigmatic example is Diamond-Blackfan anemia, caused mainly by variants in ribosomal protein genes and, more rarely, in other genes associated with the syndrome, in addition to rare familial cases of genetically determined PRCA.

Pathogenesis and pathophysiology

The pathogenesis of pure red cell aplasia is based on a selective and nearly complete block of proliferation and maturation of the erythroid lineage in the bone marrow, with functional preservation of the granulocytic and megakaryocytic lineages. This unique pattern reflects the interaction of multiple pathogenic mechanisms whose relative importance varies according to the underlying etiology.

In acquired immune mediated forms, which account for most adult cases, injury is sustained by aberrant activation of cytotoxic T lymphocytes or by production of autoantibodies directed against erythroblast antigens. Once activated, CD8+ T lymphocytes recognize specific antigens on the surface of erythroid precursors and destroy them through release of interferon gamma and TNF alpha, which induce apoptosis and inhibit proliferation. Autoantibodies may instead opsonize or selectively block red cell lineage cells, causing a restricted cytopenia without involvement of the other lineages.

In cases secondary to parvovirus B19 infection, the pathophysiology is substantially different: the virus uses transferrin receptor 1 (TfR1/CD71) through VP1u to enter erythroid precursors selectively; globoside (P antigen) acts at a postentry stage. Active viral replication then causes erythroblast lysis. This leads to collapse of red blood cell production, with almost complete arrest of reticulocyte production; viral persistence in immunocompromised individuals prevents normal resolution of the disorder.

In paraneoplastic PRCA, particularly in association with thymoma or lymphoproliferative disorders, erythroblast injury results from profound alteration of immune surveillance: loss of immune tolerance or production of dysfunctional T lymphocytes promotes selective attack against red cell lineage precursors, often mediated by altered regulatory T cell repertoires.

In congenital forms, particularly Diamond-Blackfan anemia, variants in ribosomal protein genes or other genes associated with the syndrome impair erythroid production through convergent mechanisms that may include ribosomal stress, p53 activation, and apoptosis of erythroid progenitors. The final result is ineffective erythroblast maturation and a severe quantitative deficit of mature red blood cells despite preservation of the remainder of hematopoiesis.

From a pathophysiologic perspective, the almost complete absence of bone marrow erythroblasts causes a progressive reduction in red blood cell mass and a drastic decrease in the reticulocyte count, while the number and morphology of the other lineages remain normal. The body activates compensatory mechanisms, including increased 2,3-diphosphoglycerate and increased cardiac output, but these are insufficient in severe forms, causing acute symptoms and, in chronic cases, a high risk of organ failure secondary to severe tissue hypoxia.

Clinical presentation

The clinical onset of pure red cell aplasia can range from subclinical forms discovered incidentally to progressive severe anemia requiring prompt intervention. The distinguishing feature that guides diagnostic suspicion from the outset is isolated anemia, generally normocytic and normochromic, accompanied by a marked reduction in the reticulocyte count, without clinical or laboratory signs of involvement of the other hematopoietic lineages.

On history, patients typically report progressive fatigue, dyspnea related to physical activity, tachycardia, and exercise intolerance. In chronic disease there is progressive limitation of daily activities, whereas acute forms rapidly progress to signs of diffuse tissue hypoxia.

The clinical signs on physical examination are dominated by cutaneous and mucosal pallor, frequently associated with sinus tachycardia, a low volume pulse, and a functional hyperdynamic systolic murmur. In more advanced cases, dyspnea at rest, presyncope, cold sweating, and, in predisposed individuals, exertional angina or worsening of preexisting ischemic heart disease may occur. In children, symptoms may be subtle and manifest as growth impairment, irritability, or anorexia.

The distinctive feature of PRCA is the absence of signs of bleeding, recurrent infections, or cutaneous and mucosal hemorrhagic manifestations because granulocyte and platelet function remains intact. The absence of hepatosplenomegaly, lymphadenopathy, or other organ abnormalities, which may instead be present in pancytopenias secondary to infiltrative or systemic diseases, provides an additional differential feature.

In forms associated with autoimmune diseases, thymoma, or lymphoproliferative neoplasms, the clinical picture may be complicated by symptoms and signs typical of the underlying disorder, including fever, arthralgia, skin rashes, lymphadenopathy, and mediastinal masses, but isolated anemia remains the dominant manifestation.

In summary, the clinical presentation of pure red cell aplasia is characterized by pure, severe, hyporegenerative anemia that manifests predominantly with nonspecific symptoms of tissue hypoxia and objective signs of hemodynamic compensation, in the absence of pancytopenia or morphologic abnormalities of the other hematopoietic lineages.

Diagnostic evaluation and diagnosis

The diagnostic workup for pure red cell aplasia requires a rigorous approach based on integration of clinical, laboratory, and morphologic data, with the aim of documenting selective blockade of the erythroid lineage and excluding the many conditions that can mimic isolated hyporegenerative anemia.

The pathway begins with clinical suspicion, based on normocytic, normochromic anemia, often severe and progressive, associated with a profoundly reduced reticulocyte count and no significant abnormalities in the leukocyte and platelet lineages. At this stage, the complete blood count is the first tool and provides quantitative evidence of selective cytopenia.

On the peripheral blood smear, erythrocytes appear morphologically normal or only mildly abnormal, without signs of hemolysis, schistocytes, inclusions, or other features suggesting infiltrative or hemolytic disease. Leukocyte and platelet counts are generally within normal limits, a fundamental differential feature compared with other forms of bone marrow failure.

A definitive diagnosis is obtained by bone marrow examination. Bone marrow aspiration and, when indicated, bone marrow biopsy document overall normal marrow cellularity, with almost complete absence of erythroid precursors, while the granulocytic and megakaryocytic lineages remain preserved. This finding is characteristic of PRCA but not pathognomonic and must be interpreted in the etiologic and diagnostic context. It allows distinction from aplastic anemia, in which all cell lineages are reduced, and from myelodysplastic syndromes, in which dysplasia, cytogenetic or molecular abnormalities, and other clonal findings may be present.

Once the morphologic diagnosis has been confirmed, a series of investigations targeted at identifying the etiology is performed because of the prognostic and therapeutic importance of the underlying cause. The following should therefore be investigated:

• Viral infections, especially parvovirus B19 but also HIV, EBV, hepatitis viruses, and CMV: by peripheral blood PCR and specific serology;
• Lymphoproliferative disorders and thymoma: imaging studies, including chest CT, abdominal ultrasound, and PET, serum protein electrophoresis, and lymphocyte studies;
• Large granular lymphocyte proliferation/T-LGLL: morphologic and immunophenotypic assessment by flow cytometry, integrated with evaluation of TCR clonality when indicated;
• Autoimmune diseases: autoantibody assessment, including ANA, ENA, anti-DNA antibodies, and rheumatoid factor, with screening for the main connective tissue diseases;
• Drugs and toxic substances: detailed medication and toxic exposure history with withdrawal of suspected agents when appropriate;
• Congenital forms: study of genes associated with congenital erythroid failure, including ribosomal protein genes such as RPS19, RPL5, and RPL11 and, separately, GATA1.

In adults, cytogenetic and molecular analysis of the bone marrow is also often indicated to exclude myelodysplasia and identify rare genetically determined forms of PRCA.

The differential diagnosis includes all conditions that can cause severe anemia with low reticulocytes: aplastic anemia, which is associated with pancytopenia and generalized bone marrow hypocellularity; myelodysplastic syndromes; neoplastic bone marrow infiltration; profound nutritional deficiencies; chronic infections; and end stage renal disease. Documentation of selective aplasia of the erythroid lineage alone, in the absence of other abnormalities, remains the key finding for the diagnosis of PRCA.

Treatment and prognosis

The therapeutic strategy for pure red cell aplasia is based on precise identification of the underlying cause and on the severity of the clinical presentation, with the goal of restoring effective red blood cell production, preventing complications of severe anemia and, when possible, removing or controlling the etiologic factor.

In secondary acquired forms, causal treatment is the cornerstone of the approach: elimination of the responsible agent, such as a drug or toxic substance, or treatment of the associated disorder, including eradication of viral infections, control of neoplasms, and management of autoimmune diseases, can in many cases lead to remission of the syndrome and normalization of erythropoiesis.

Particular attention should be paid to forms associated with parvovirus B19: in immunocompetent patients, infection is self-limiting and resolves spontaneously, whereas in immunocompromised individuals, high dose intravenous immunoglobulin is the treatment of choice and often produces a rapid and complete response.

In idiopathic or immune mediated forms, first line therapy is generally based on cyclosporine A, with or without corticosteroids according to the clinical profile. In refractory or relapsing cases, other immunosuppressants such as cyclophosphamide, azathioprine, or mycophenolate mofetil may be considered. Rituximab, an anti-CD20 monoclonal antibody, has proved effective in forms secondary to lymphoproliferative or autoimmune disorders. In patients with thymoma, surgical treatment of the neoplasm may, although not always, result in resolution of PRCA.

Transfusion support with packed red blood cells is often necessary during acute phases or in resistant forms, with careful monitoring of the risk of iron overload. In chronic cases, iron chelation may be indicated to prevent secondary siderosis.

Congenital forms, such as Diamond-Blackfan anemia, instead require specific management based on high dose corticosteroids, periodic transfusions, and, in selected cases, allogeneic hematopoietic stem cell transplantation, which is the only option capable of definitively correcting the hematopoietic defect, particularly in children with disease refractory to conventional therapies.

Prognosis varies with etiology. Reversible secondary forms may resolve; immune mediated forms may relapse. In congenital syndromes, particularly Diamond-Blackfan anemia, prognosis depends on the anemia, therapies, iron overload, and specific cancer predisposition; this risk cannot be generalized to every form of PRCA.

Follow-up includes complete blood counts, reticulocyte counts, transfusion requirements, iron status, and organ function, together with monitoring of the underlying cause and treatment toxicity.

Complications

Complications of pure red cell aplasia arise predominantly from the severity and duration of anemia, as well as from the adverse effects of the immunosuppressive and transfusion therapies required to control the disease. Although preservation of the other hematopoietic lineages limits the infectious and hemorrhagic risks typical of global pancytopenia, chronic or refractory forms of PRCA carry a significant risk of adverse events, sometimes potentially fatal.

The immediate risk, particularly during acute phases or in patients with severe uncompensated anemia, is persistent tissue hypoxia, which can cause angina pectoris, arrhythmias, heart failure, organ ischemia and, in extreme cases, sudden death, especially in older individuals or those with preexisting cardiovascular disease.

Chronic transfusion support, when necessary for prolonged periods, exposes patients to cumulative complications such as iron overload, or hemosiderosis, with possible injury to the liver, heart, and endocrine system, and formation of red blood cell alloantibodies, which may reduce the effectiveness of subsequent transfusions and complicate compatibility for possible transplantation. Acute transfusion reactions and the now reduced risk of viral infection transmission also remain aspects that require monitoring.

In patients treated with prolonged immunosuppressive therapy, including steroids, cyclosporine, rituximab, and cyclophosphamide, there is an increased incidence of opportunistic infections, bacterial, fungal, and viral, reactivation of latent infections and, more rarely, organ toxicity involving the kidneys, liver, or metabolism. Chronic corticosteroid use may cause osteoporosis, hyperglycemia, myopathy, cataracts, and Cushing syndrome.

In congenital forms such as Diamond-Blackfan anemia, long term complications include the risk of growth delay, associated congenital abnormalities, development of hematologic and nonhematologic malignancies, and progressive organ failure due to siderosis.

In forms associated with thymoma or lymphoproliferative disorders, the underlying neoplasm may progress; PRCA itself, however, is not a clonal precursor of myelodysplastic syndrome or acute leukemia.

Timely recognition and multidisciplinary management of complications are integral to the therapeutic pathway and are essential for improving survival and quality of life in patients with pure red cell aplasia.

Bibliography
1. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142(4):505–514.
2. Sawada K, Hirokawa M, Fujishima N. Diagnosis and management of acquired pure red cell aplasia. Hematol Oncol Clin North Am. 2009;23(2):249–259.
3. Means RT. Pure red cell aplasia. Blood. 2016;128(21):2504–2509.
4. Bain BJ. Blood Cells: A Practical Guide. Wiley-Blackwell. 5th ed. 2015.
5. Hoffbrand AV, Steensma DP. Hoffbrand’s Essential Haematology. Wiley-Blackwell. 8th ed. 2019.
6. Balasubramanian SK, Sadaps M, Thota S, et al. Rational management approach to pure red cell aplasia. Haematologica. 2018;103(2):221–230.
7. Fishman JA. Infection in organ transplantation. Am J Transplant. 2017;17(4):856–879.
8. Diamond LK, Blackfan KD. Hypoplastic anemia. Am J Dis Child. 1938;56(3):464–467.
9. Da Costa L, Narla A, Mohandas N. An update on the pathogenesis and diagnosis of Diamond-Blackfan anemia. F1000Res. 2018;7:F1000 Faculty Rev-1350.
10. Lee H, Bieri J, Ammann N, et al. Transferrin receptor 1 binds human parvovirus B19 VP1u to facilitate entry. Nat Commun. 2026;17:7443.
11. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469–475. PMID:11844847.